| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyCellularComponent | actin cytoskeleton | 2.29e-04 | 576 | 60 | 8 | GO:0015629 | |
| GeneOntologyCellularComponent | lamellipodium | 5.15e-04 | 230 | 60 | 5 | GO:0030027 | |
| GeneOntologyCellularComponent | cell leading edge | 5.55e-04 | 500 | 60 | 7 | GO:0031252 | |
| GeneOntologyCellularComponent | septin complex | 7.21e-04 | 14 | 60 | 2 | GO:0031105 | |
| GeneOntologyCellularComponent | septin ring | 7.21e-04 | 14 | 60 | 2 | GO:0005940 | |
| GeneOntologyCellularComponent | septin cytoskeleton | 9.47e-04 | 16 | 60 | 2 | GO:0032156 | |
| Domain | Teashirt_fam | 2.99e-08 | 3 | 59 | 3 | IPR027008 | |
| Pubmed | Teashirt 3 expression in the chick embryo reveals a remarkable association with tendon development. | 5.13e-09 | 3 | 61 | 3 | 16631416 | |
| Pubmed | Analysis of TSHZ2 and TSHZ3 genes in congenital pelvi-ureteric junction obstruction. | 5.13e-09 | 3 | 61 | 3 | 19745106 | |
| Pubmed | 5.13e-09 | 3 | 61 | 3 | 14973285 | ||
| Pubmed | The deubiquitinase TRABID stabilizes the K29/K48-specific E3 ubiquitin ligase HECTD1. | 9.34e-08 | 212 | 61 | 7 | 33853758 | |
| Pubmed | FE65 binds Teashirt, inhibiting expression of the primate-specific caspase-4. | 1.79e-07 | 7 | 61 | 3 | 19343227 | |
| Pubmed | 2.86e-07 | 8 | 61 | 3 | 15834955 | ||
| Pubmed | Mechanosensitive mTORC1 signaling maintains lymphatic valves. | 4.28e-07 | 9 | 61 | 3 | 37036444 | |
| Pubmed | 7.21e-07 | 95 | 61 | 5 | 20843830 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 10691930 | ||
| Pubmed | [The study on the haplotype of MICA and MICB microsatellite locus in Guangzhou Han population]. | 3.03e-06 | 2 | 61 | 2 | 15640005 | |
| Pubmed | MICA/B expression in macrophage foam cells infiltrating atherosclerotic plaques. | 3.03e-06 | 2 | 61 | 2 | 24997223 | |
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 28677817 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 26902929 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 36958849 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 33835601 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 18511496 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 21388352 | ||
| Pubmed | Diversity and characterization of polymorphic 5' promoter haplotypes of MICA and MICB genes. | 3.03e-06 | 2 | 61 | 2 | 24962621 | |
| Pubmed | A role for the MHC class I-like Mill molecules in nutrient metabolism and wound healing. | 3.03e-06 | 2 | 61 | 2 | 18560379 | |
| Pubmed | Association of MICA and MICB alleles with symptomatic dengue infection. | 3.03e-06 | 2 | 61 | 2 | 21762746 | |
| Pubmed | In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer. | 3.03e-06 | 2 | 61 | 2 | 17565371 | |
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 19949079 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 16776673 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 32737971 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 28334733 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 23917076 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 19553547 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 19353249 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 22227571 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 12569559 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 26708143 | ||
| Pubmed | Expression and regulation of mouse Mtsh1 during limb and branchial arch development. | 3.03e-06 | 2 | 61 | 2 | 11668608 | |
| Pubmed | Bimodal regulation of the human H1 histamine receptor by G protein-coupled receptor kinase 2. | 3.03e-06 | 2 | 61 | 2 | 15542600 | |
| Pubmed | Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. | 3.03e-06 | 2 | 61 | 2 | 12714493 | |
| Pubmed | MICA and MICB microsatellite alleles in HLA extended haplotypes. | 3.03e-06 | 2 | 61 | 2 | 11881819 | |
| Pubmed | Allelic and interlocus comparison of the PERB11 multigene family in the MHC. | 3.03e-06 | 2 | 61 | 2 | 8995188 | |
| Pubmed | Association of MICA and MICB polymorphisms with the susceptibility of leukemia in Korean patients. | 3.03e-06 | 2 | 61 | 2 | 29895953 | |
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 21423795 | ||
| Pubmed | MICB polymorphisms and haplotypes with MICA and HLA alleles in Koreans. | 3.03e-06 | 2 | 61 | 2 | 21554252 | |
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 21042760 | ||
| Pubmed | [Expression of MICA/B protein in esophageal cancer and its clinical significance]. | 3.03e-06 | 2 | 61 | 2 | 23291067 | |
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 9770516 | ||
| Pubmed | Vertebrate orthologues of the Drosophila region-specific patterning gene teashirt. | 3.03e-06 | 2 | 61 | 2 | 10704881 | |
| Pubmed | [The polymorphism distributions of MICA and MICB microsatellite in Guangdong Han population]. | 3.03e-06 | 2 | 61 | 2 | 15192843 | |
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 25228093 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 29078849 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 12242594 | ||
| Pubmed | MICA, MICB Polymorphisms and Linkage Disequilibrium with HLA-B in a Chinese Mongolian Population. | 3.03e-06 | 2 | 61 | 2 | 27028549 | |
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 8901601 | ||
| Pubmed | Structure of MHC class I-like MILL2 reveals heparan-sulfate binding and interdomain flexibility. | 3.03e-06 | 2 | 61 | 2 | 30337538 | |
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 19691640 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 29665245 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 12392511 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 21426309 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 10359807 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 28925058 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 24173243 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 34012432 | ||
| Pubmed | Wide distribution of the MICA-MICB null haplotype in East Asians. | 3.03e-06 | 2 | 61 | 2 | 11169252 | |
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 21605422 | ||
| Pubmed | MIC gene polymorphism and haplotype diversity in Zhuang nationality of Southern China. | 3.03e-06 | 2 | 61 | 2 | 25167773 | |
| Pubmed | A new polymorphic and multicopy MHC gene family related to nonmammalian class I. | 3.03e-06 | 2 | 61 | 2 | 7927538 | |
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 14662896 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 24058482 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 30471210 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 12466900 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 16969495 | ||
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 34482362 | ||
| Pubmed | Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. | 3.03e-06 | 2 | 61 | 2 | 9497295 | |
| Pubmed | 3.03e-06 | 2 | 61 | 2 | 35525711 | ||
| Pubmed | MICB microsatellite polymorphism is associated with ulcerative colitis in Chinese population. | 3.03e-06 | 2 | 61 | 2 | 16679067 | |
| Pubmed | Expression of MICA, MICB and NKG2D in human leukemic myelomonocytic and cervical cancer cells. | 9.07e-06 | 3 | 61 | 2 | 21477352 | |
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 15304009 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 12538683 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 19200602 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 24973455 | ||
| Pubmed | EGF transregulates opioid receptors through EGFR-mediated GRK2 phosphorylation and activation. | 9.07e-06 | 3 | 61 | 2 | 18463167 | |
| Pubmed | Activation of tyrosine kinase of EGFR induces Gbetagamma-dependent GRK-EGFR complex formation. | 9.07e-06 | 3 | 61 | 2 | 15620700 | |
| Pubmed | Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. | 9.07e-06 | 3 | 61 | 2 | 12384702 | |
| Pubmed | The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. | 9.07e-06 | 3 | 61 | 2 | 20428196 | |
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 18791713 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 16920948 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 25363527 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 21857986 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 16101830 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 16568261 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 18287244 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 27026046 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 26071561 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 22415659 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 16923796 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 17584663 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 17202358 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 17625602 | ||
| Pubmed | 9.07e-06 | 3 | 61 | 2 | 16435885 | ||
| Pubmed | MHC class I chain-related gene B (MICB) is associated with rheumatoid arthritis susceptibility. | 9.07e-06 | 3 | 61 | 2 | 17003176 | |
| Pubmed | 1.81e-05 | 4 | 61 | 2 | 29339534 | ||
| Pubmed | 1.81e-05 | 4 | 61 | 2 | 25775242 | ||
| Pubmed | 1.81e-05 | 4 | 61 | 2 | 23526433 | ||
| Pubmed | The role of FREM2 and FRAS1 in the development of congenital diaphragmatic hernia. | 1.81e-05 | 4 | 61 | 2 | 29618029 | |
| Interaction | TSHZ1 interactions | 1.11e-05 | 15 | 60 | 3 | int:TSHZ1 | |
| GeneFamily | Zinc fingers C2H2-type|ZF class homeoboxes and pseudogenes | 6.00e-06 | 15 | 44 | 3 | 529 | |
| GeneFamily | Septins | 4.44e-04 | 13 | 44 | 2 | 732 | |
| GeneFamily | Zinc fingers C2H2-type|ZF class homeoboxes and pseudogenes | 1.61e-03 | 718 | 44 | 7 | 28 | |
| GeneFamily | C1-set domain containing | 4.68e-03 | 42 | 44 | 2 | 591 | |
| CoexpressionAtlas | dev gonad_e12.5_F_VasAssMesen_MafB_top-relative-expression-ranked_1000 | CFH SLC41A2 HDAC3 COL6A1 FAT4 ACACA TSHZ2 ZNF521 ZC3H12B TSHZ1 ADCY2 ZMAT1 PALLD | 1.78e-07 | 783 | 59 | 13 | gudmap_dev gonad_e12.5_F_VasAssMesen_MafB_1000 |
| CoexpressionAtlas | dev gonad_e13.5_F_VascAssocMesenchStromOvary_MafB_top-relative-expression-ranked_500 | 6.20e-06 | 357 | 59 | 8 | gudmap_dev gonad_e13.5_F_VascAssocMesenchStromOvary_MafB_500 | |
| CoexpressionAtlas | dev gonad_e11.5_M_GonadVasMes_Flk_top-relative-expression-ranked_1000 | HDAC3 CASP8AP2 ACACA TSHZ2 ZNF521 SEPTIN11 TSHZ1 ADCY2 ZMAT1 PALLD KLHL4 | 1.48e-05 | 827 | 59 | 11 | gudmap_dev gonad_e11.5_M_GonadVasMes_Flk_1000 |
| CoexpressionAtlas | dev gonad_e13.5_F_VascAssocMesenchStromOvary_MafB_k-means-cluster#3_top-relative-expression-ranked_500 | 2.25e-05 | 122 | 59 | 5 | gudmap_dev gonad_e13.5_F_VascAssocMesenchStromOvary_MafB_k3_500 | |
| CoexpressionAtlas | dev gonad_e12.5_M_InterstitLeydig_MafB_k-means-cluster#1_top-relative-expression-ranked_1000 | 2.35e-05 | 310 | 59 | 7 | gudmap_dev gonad_e12.5_M_InterstitLeydig_MafB_k1_1000 | |
| CoexpressionAtlas | dev gonad_e13.5_F_VascAssocMesenchStromOvary_MafB_top-relative-expression-ranked_1000 | CFH SLC41A2 COL6A1 FAT4 TSHZ2 ZNF521 TSHZ1 ADCY2 ZMAT1 PALLD | 3.33e-05 | 740 | 59 | 10 | gudmap_dev gonad_e13.5_F_VascAssocMesenchStromOvary_MafB_1000 |
| CoexpressionAtlas | dev gonad_e12.5_M_InterstitLeydig_MafB_top-relative-expression-ranked_1000 | CFH COL6A1 TSHZ2 ZNF521 SEPTIN11 ZC3H12B ADCY2 ZMAT1 PALLD KLHL4 | 4.56e-05 | 768 | 59 | 10 | gudmap_dev gonad_e12.5_M_InterstitLeydig_MafB_1000 |
| CoexpressionAtlas | dev gonad_e11.5_F_GonadVasMes_Flk_top-relative-expression-ranked_1000 | FAT4 FRAS1 TSHZ2 ZNF521 ZC3H12B TSHZ1 ADCY2 ZMAT1 PALLD KLHL4 | 8.80e-05 | 831 | 59 | 10 | gudmap_dev gonad_e11.5_F_GonadVasMes_Flk_1000 |
| CoexpressionAtlas | dev gonad_e13.5_F_VascAssocMesenchStromOvary_MafB_k-means-cluster#2_top-relative-expression-ranked_1000 | 9.24e-05 | 265 | 59 | 6 | gudmap_dev gonad_e13.5_F_VascAssocMesenchStromOvary_MafB_k2_1000 | |
| CoexpressionAtlas | DevelopingKidney_e14.5 whole kidney - Wnt4 KO_emap-6674_top-relative-expression-ranked_500 | 9.70e-05 | 388 | 59 | 7 | gudmap_developingKidney_e14.5 whole kidney - Wnt4 KO_500 | |
| CoexpressionAtlas | DevelopingKidney_e14.5 whole kidney - Wnt4 KO_emap-6674_k-means-cluster#3_top-relative-expression-ranked_500 | 1.75e-04 | 188 | 59 | 5 | gudmap_developingKidney_e14.5 whole kidney - Wnt4 KO_500_k3 | |
| CoexpressionAtlas | DevelopingKidney_e15.5_Peripheral blastema_emap-27731_k-means-cluster#3_top-relative-expression-ranked_1000 | 2.06e-04 | 307 | 59 | 6 | gudmap_developingKidney_e15.5_Peripheral blastema_1000_k3 | |
| CoexpressionAtlas | Stromal Cells, LEC.MLN, gp38+ CD31+, Lymph Node, avg-4 | 2.08e-04 | 439 | 59 | 7 | GSM777059_500 | |
| CoexpressionAtlas | dev gonad_e12.5_F_VasAssMesen_MafB_k-means-cluster#3_top-relative-expression-ranked_1000 | 2.24e-04 | 107 | 59 | 4 | gudmap_dev gonad_e12.5_F_VasAssMesen_MafB_k3_1000 | |
| CoexpressionAtlas | Stromal Cells, LEC.SLN, gp38+ CD31+, Lymph Node, avg-4 | 2.42e-04 | 450 | 59 | 7 | GSM777063_500 | |
| CoexpressionAtlas | Stromal Cells, BEC.SLN, gp38- CD31+, Lymph Node, avg-4 | 2.72e-04 | 459 | 59 | 7 | GSM777037_500 | |
| CoexpressionAtlas | dev gonad_e13.5_M_InterstitTestis_Sma_top-relative-expression-ranked_1000 | 2.74e-04 | 777 | 59 | 9 | gudmap_dev gonad_e13.5_M_InterstitTestis_Sma_1000 | |
| CoexpressionAtlas | DevelopingKidney_e14.5 whole kidney - Wnt4 KO_emap-6674_top-relative-expression-ranked_1000 | 3.12e-04 | 791 | 59 | 9 | gudmap_developingKidney_e14.5 whole kidney - Wnt4 KO_1000 | |
| CoexpressionAtlas | dev gonad_e12.5_F_VasAssocMesStromOvary_Sma_top-relative-expression-ranked_1000 | SLC41A2 HDAC3 FAT4 DCAF12L1 ZNF521 ZC3H12B TSHZ1 ADCY2 PALLD | 3.30e-04 | 797 | 59 | 9 | gudmap_dev gonad_e12.5_F_VasAssocMesStromOvary_Sma_1000 |
| CoexpressionAtlas | dev gonad_e13.5_M_InterstitFLeydig_MafB_k-means-cluster#3_top-relative-expression-ranked_1000 | 3.34e-04 | 336 | 59 | 6 | gudmap_dev gonad_e13.5_M_InterstitFLeydig_MafB_k3_1000 | |
| ToppCell | Control-Fibroblasts-Other_FB|Control / group, cell type (main and fine annotations) | 1.87e-10 | 187 | 61 | 8 | bd3739c4a52aa1ba5deffd778e113a9800f7e158 | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 1.03e-08 | 198 | 61 | 7 | 21cf4d81386761d09d0f6829c01c198e5524176d | |
| ToppCell | COVID-19-Fibroblasts-Other_FB|COVID-19 / group, cell type (main and fine annotations) | 2.63e-07 | 193 | 61 | 6 | e6b75be08e33c1de079fb5c02f0b4468128b369c | |
| ToppCell | Mesenchymal-matrix_fibroblast_1_cell|World / Lineage, Cell type, age group and donor | 2.63e-07 | 193 | 61 | 6 | acad568621ed677031797b8c2e34dafea798d681 | |
| ToppCell | Control-Fibroblasts-Intermediate_pathological_FB|Control / group, cell type (main and fine annotations) | 2.71e-07 | 194 | 61 | 6 | 03a269f75a481ea54aea8e6444605db8d6df493d | |
| ToppCell | PCW_05-06-Mesenchymal|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 2.88e-07 | 196 | 61 | 6 | dca52c57ba35d9395cdbca8b881f12ece721b10f | |
| ToppCell | COVID-19-Fibroblasts-Intermediate_pathological_FB|COVID-19 / group, cell type (main and fine annotations) | 2.97e-07 | 197 | 61 | 6 | f1c8936986123a3151140c374fcd62d6705c530b | |
| ToppCell | LPS_IL1RA-Endothelial-Endothelial-Gen_Cap|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 3.24e-07 | 200 | 61 | 6 | dccec522ab0d7fff62ad6273b02aa9022dbbb8eb | |
| ToppCell | LPS_only-Endothelial-Endothelial-Gen_Cap|LPS_only / Treatment groups by lineage, cell group, cell type | 3.24e-07 | 200 | 61 | 6 | eb94a5111ef0e903ee5be9f7efe571b4e6d5fce1 | |
| ToppCell | Control|World / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.43e-06 | 177 | 61 | 5 | b8ff6940e31b749776e81ae4f5bbd577dba9749c | |
| ToppCell | E16.5-samps-Endothelial-Immature_fetal_endothelial-Proliferative_Endothelial|E16.5-samps / Age Group, Lineage, Cell class and subclass | 4.68e-06 | 179 | 61 | 5 | d24513a404c9b1d37dd47aa1cdb5713b64b88f89 | |
| ToppCell | COVID-19-Heart-Lymph_EC|Heart / Disease (COVID-19 only), tissue and cell type | 4.68e-06 | 179 | 61 | 5 | 411620201a860716a8773b92f50f7b94ef34a586 | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 5.79e-06 | 187 | 61 | 5 | a9316e2818217ec5feae9cf8816f7249803caee6 | |
| ToppCell | COVID-19-lung-Artery_EC|lung / Disease (COVID-19 only), tissue and cell type | 5.94e-06 | 188 | 61 | 5 | eecd7482b3c97d7f49993cb17edfab30c61232fc | |
| ToppCell | Control-Fibroblasts-Adventitial_FB|Control / group, cell type (main and fine annotations) | 5.94e-06 | 188 | 61 | 5 | 706a26c372add839d947749f0521a0e1f5c9b0ec | |
| ToppCell | Mesenchymal-myofibroblast_cell|World / Lineage, Cell type, age group and donor | 6.10e-06 | 189 | 61 | 5 | 44e37f88137bb249933eb615235b2cf2ae7f3925 | |
| ToppCell | 3'-Adult-LargeIntestine-Mesenchymal-myocytic|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.10e-06 | 189 | 61 | 5 | f7e2ee5047792ab9ef6472fa88e2d193cdea6fa0 | |
| ToppCell | PCW_07-8.5-Epithelial-Epithelial_airway-epi_proximal_progenitor1_(6)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 6.10e-06 | 189 | 61 | 5 | 7659c7bbd58ee959a159294fb8d17317bbcc5681 | |
| ToppCell | Fetal_29-31_weeks-Endothelial-endothelial_cell_of_lymph_vessel|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 6.10e-06 | 189 | 61 | 5 | 55a1776a4ce049959b3f13a43744c7314bc1f00a | |
| ToppCell | 3'-Adult-LargeIntestine-Mesenchymal-myocytic-myofibroblast_(RSPO2+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.10e-06 | 189 | 61 | 5 | 63449d9f1e78ff2bc8786eb88a0d177fe30c7f4d | |
| ToppCell | COVID-19-lung-Artery_EC|COVID-19 / Disease (COVID-19 only), tissue and cell type | 6.26e-06 | 190 | 61 | 5 | 07b675befcd1d0a9c90cb17b5d22323468325d51 | |
| ToppCell | LPS_only-Endothelial-Endothelial-Alv_Cap|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.26e-06 | 190 | 61 | 5 | 474cbbab8f3b0a6881fa6c92edb78e43999f9ab0 | |
| ToppCell | PCW_07-8.5-Epithelial-Epithelial_airway-epi_proximal_secretory_(0)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 6.42e-06 | 191 | 61 | 5 | 60ff989fe99d243a3d52955223680cdd1f1917a4 | |
| ToppCell | nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 6.42e-06 | 191 | 61 | 5 | 6688cee34beee4f151ac17fccbc9c26a9aad72e1 | |
| ToppCell | 10x3'2.3-week_14-16-Endothelial-stroma-immature_EC|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 6.58e-06 | 192 | 61 | 5 | 5af3b2b38495e925497c48f605d618bbf970965d | |
| ToppCell | LPS-antiTNF-Endothelial-Endothelial-Activated_Alv_Cap|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.58e-06 | 192 | 61 | 5 | c618ede75dce3988c87a5b8f98d8e94e1dd66efd | |
| ToppCell | LPS-IL1RA+antiTNF-Endothelial|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.58e-06 | 192 | 61 | 5 | 04f5a2e3dd6beff027b89d66eefdd92036e041af | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-myofibroblast_cell-D150|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 6.58e-06 | 192 | 61 | 5 | 72881b280a415e65f87a80ca1369cbb0b722a0c4 | |
| ToppCell | LPS-IL1RA+antiTNF-Endothelial-Endothelial|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.58e-06 | 192 | 61 | 5 | c07d7b40b2aa4eb27ac85801c014a656e2fd01dc | |
| ToppCell | COVID-19-Heart-Fib_+_EC_+_Pericyte|Heart / Disease (COVID-19 only), tissue and cell type | 6.58e-06 | 192 | 61 | 5 | 60b1312e84f6d6448365a952469c506c00b5fe93 | |
| ToppCell | PCW_07-8.5-Epithelial-Epithelial_neuroendo-epi_NE_progenitor_(7)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 6.58e-06 | 192 | 61 | 5 | b99f8236ef4ccdc75c02abea381cae6453205f6f | |
| ToppCell | facs-Brain_Myeloid-Hippocampus-3m-Myeloid|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.75e-06 | 193 | 61 | 5 | 06b65110db974f4ef90d3511ff34428976a52c9c | |
| ToppCell | LPS-IL1RA+antiTNF-Endothelial-Endothelial-Gen_Cap|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.75e-06 | 193 | 61 | 5 | e09387af84d2a0a526e54d4793e6e06c6739db53 | |
| ToppCell | facs-Brain_Myeloid-Hippocampus-3m-Myeloid-microglial_cell|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.75e-06 | 193 | 61 | 5 | 9c16032bc03df8760ae199e8f19fdafa4c3f1827 | |
| ToppCell | LPS-antiTNF-Endothelial-Endothelial-Gen_Cap|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.75e-06 | 193 | 61 | 5 | 6e1982d089a9de628e6006d23ff78a223fbd9f47 | |
| ToppCell | Epithelial-club_cell|World / Lineage, Cell type, age group and donor | 6.75e-06 | 193 | 61 | 5 | 2bdd09004fa433550958ec42ba4b06271a4aaf7c | |
| ToppCell | Control-Endothelial-Endothelial|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.75e-06 | 193 | 61 | 5 | aff0649c73c634bc6ff0dc7759b4693a9236bf05 | |
| ToppCell | facs-Brain_Myeloid-Hippocampus-3m|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.75e-06 | 193 | 61 | 5 | a4f91bca5eaa985982d33a528f7566ffde154d47 | |
| ToppCell | Control-Endothelial|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.75e-06 | 193 | 61 | 5 | c5f9fe03e64c211d4bcd4959e5b32f14841e336a | |
| ToppCell | Control-Endothelial-Endothelial-Gen_Cap|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.75e-06 | 193 | 61 | 5 | e1d546165dcc2392f540162206852c4717d7306f | |
| ToppCell | facs-Brain_Myeloid-Hippocampus-3m-Myeloid-nan|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.75e-06 | 193 | 61 | 5 | b39d7feaac4ff8f7409cd3d15e8f3c6391367275 | |
| ToppCell | LPS-IL1RA-Endothelial|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.92e-06 | 194 | 61 | 5 | 43f92b0533e26633dc94cce554045d641ef8fd76 | |
| ToppCell | LPS-IL1RA-Endothelial-Endothelial-Gen_Cap|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.92e-06 | 194 | 61 | 5 | 0b9cd96fa0b616da7cc90e92ff71157e9bba518f | |
| ToppCell | LPS-IL1RA-Endothelial-Endothelial|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.92e-06 | 194 | 61 | 5 | 1d39d968730a7e85b6161c1c8a6bd38afe9bcad7 | |
| ToppCell | PCW_07-8.5-Epithelial-Epithelial_airway|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 6.92e-06 | 194 | 61 | 5 | f95c8dc242c9aebcadfe61b1ed033349cb7e5a88 | |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_myofibroblast|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 7.10e-06 | 195 | 61 | 5 | f5e91ce20a7ce528dc4c1a968c7bf096bf45c528 | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 7.28e-06 | 196 | 61 | 5 | 22538376a95fe3afe8639a216a5497087aa94110 | |
| ToppCell | 11.5-Distal-Epithelial-Secretory_progenitor|Distal / Age, Tissue, Lineage and Cell class | 7.28e-06 | 196 | 61 | 5 | 2648d64b0e7b59ae78182d55f32699ceea37ff8d | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 7.46e-06 | 197 | 61 | 5 | 44673c38384453207871d3fd8e8ba9093cc06bc5 | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_myofibroblast|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 7.46e-06 | 197 | 61 | 5 | 6d0d68d460243a0259ada93ebda40fa7b3088eeb | |
| ToppCell | IPF-Stromal-Myofibroblast|Stromal / Disease state, Lineage and Cell class | 7.46e-06 | 197 | 61 | 5 | f304d42fc4936fe20996e07c8dccc698a6e5e5ef | |
| ToppCell | E16.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-PMP|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 7.64e-06 | 198 | 61 | 5 | 148f5fee19ea8dff7f2de4ca69c3b03e5221985d | |
| ToppCell | Parenchymal-NucSeq-Endothelial-Endothelia_lymphatic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 7.64e-06 | 198 | 61 | 5 | 9ab0db78394e730f6866b2db80047149024ad5f6 | |
| ToppCell | COVID-19-lung-Fibroblast|lung / Disease (COVID-19 only), tissue and cell type | 7.64e-06 | 198 | 61 | 5 | df3de77216f5c5d6141ec44d01c56b942f611838 | |
| ToppCell | Bronchial-NucSeq-Endothelial-Endothelia_lymphatic-Endothelia_Lymphatic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 7.64e-06 | 198 | 61 | 5 | b3a020522e064bb61949d38e442f24026e339364 | |
| ToppCell | Bronchial-NucSeq-Endothelial-Endothelia_lymphatic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 7.64e-06 | 198 | 61 | 5 | fc4b7c3ad52bc5c8b40fa04a156bfbb58afa2872 | |
| ToppCell | Parenchymal-NucSeq-Endothelial-Endothelia_lymphatic-Endothelia_Lymphatic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 7.64e-06 | 198 | 61 | 5 | e47d0e2c6353315c85d7007742bb16b0f05795ed | |
| ToppCell | Fetal_29-31_weeks|World / Lineage, Cell type, age group and donor | 7.83e-06 | 199 | 61 | 5 | 5b9d355795dd03a22f0961dfd143425c367a4654 | |
| ToppCell | Mesenchymal|World / Lineage, Cell type, age group and donor | 7.83e-06 | 199 | 61 | 5 | 4bac110c2b3609f6ee5d0e3275da0824a6240270 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_myocytic-Myofibroblastic-MatrixFB_->_Myofibroblast|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 7.83e-06 | 199 | 61 | 5 | 38cfd367ee8c074c11ba54edeb7a001e375e2687 | |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_perichondrial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 7.83e-06 | 199 | 61 | 5 | abd6117f8a3d7e798d8471c16d97b34aaf50fc9c | |
| ToppCell | Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-3|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 8.02e-06 | 200 | 61 | 5 | e663995fc44c340d878d66b278b7b5c2ff784301 | |
| ToppCell | control-Epithelial|control / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 8.02e-06 | 200 | 61 | 5 | f95bbb94e51ac28b1995026c599ec3a34e012916 | |
| ToppCell | LPS_IL1RA_TNF-Epithelial_airway-airway_epithelial-Ciliated|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 8.02e-06 | 200 | 61 | 5 | 96701a4d57753f5ec0dd5c7550054bbcc946bc5f | |
| ToppCell | Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-1|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 8.02e-06 | 200 | 61 | 5 | c3d4ce70ab51d74c9fe2f5864e52a4a9d7570e10 | |
| ToppCell | NS-control-d_0-4-Epithelial|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 8.02e-06 | 200 | 61 | 5 | d014959891893b6d3854a471fba1dc50c6625a0a | |
| ToppCell | Parenchyma_Control_(B.)-Stromal-TX-Fibroblasts-1|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type | 8.02e-06 | 200 | 61 | 5 | aa1a35dcca3b799241eef4237f6eb94660e019f0 | |
| ToppCell | Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-4-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 8.02e-06 | 200 | 61 | 5 | 4dbe21cb63569f28c7017cda065ea5ee00d7254e | |
| ToppCell | Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-1-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 8.02e-06 | 200 | 61 | 5 | 137f8f9d255c66336d4f8b44b2e3f3de721f2bf0 | |
| ToppCell | Control_saline-Mesenchymal_myocytic-Myofibroblastic-MatrixFB_->_Myofibroblast|Control_saline / Treatment groups by lineage, cell group, cell type | 8.02e-06 | 200 | 61 | 5 | a799fc7bb83ad0524362cb5010df949741fb7bf3 | |
| ToppCell | Parenchyma_COVID-19-Stromal-TX-Fibroblasts-4|Parenchyma_COVID-19 / Sample group, Lineage and Cell type | 8.02e-06 | 200 | 61 | 5 | bde938e5a18844fb8cc1d1be5a086809f7e2b97d | |
| ToppCell | Transplant_Alveoli_and_parenchyma-Mesenchymal-Mesothelium|Transplant_Alveoli_and_parenchyma / Tissue, Lineage and Cell class of Lung Cells from 10X | 8.02e-06 | 200 | 61 | 5 | c082bc21ec7c5323439d108ea8aea510e1113c3f | |
| ToppCell | Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-1|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 8.02e-06 | 200 | 61 | 5 | a510deaada669e690329183e18df02870bd204b3 | |
| ToppCell | Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-4|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 8.02e-06 | 200 | 61 | 5 | 8256511b099c3eab8e33194f90c9ff354e7cfe8e | |
| ToppCell | Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-3-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 8.02e-06 | 200 | 61 | 5 | 2cb8a39a12522a9643c6244d5e94cb4559868bb9 | |
| ToppCell | Lung_Parenchyma-Severe-Mesenchymal|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 8.02e-06 | 200 | 61 | 5 | 6ce8e2cf689523993d909a27daec3d6a5824d13c | |
| ToppCell | Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 8.02e-06 | 200 | 61 | 5 | 907427e85cebe5a18c8a310e2ffa0e180ea3cb77 | |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 8.02e-06 | 200 | 61 | 5 | cae972324d1dfea6efeaf6013f265c7c6bb48db4 | |
| ToppCell | Parenchyma_COVID-19-Stromal-TX-Fibroblasts-3|Parenchyma_COVID-19 / Sample group, Lineage and Cell type | 8.02e-06 | 200 | 61 | 5 | 8cc5057b0e5ae9b72ea40d2ffbc52b79bf87ccef | |
| ToppCell | LPS_IL1RA_TNF-Endothelial-Endothelial-Gen_Cap|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 8.02e-06 | 200 | 61 | 5 | b2d4e6f3e8e4da62e6b02758ab2ed8f505269f9a | |
| ToppCell | Parenchyma_COVID-19-Stromal-TX-Fibroblasts-1|Parenchyma_COVID-19 / Sample group, Lineage and Cell type | 8.02e-06 | 200 | 61 | 5 | 25d3865aa2ced11a5ed40013e83b47d942fdf582 | |
| ToppCell | Fibroblast|World / shred by cell class for parenchyma | 8.02e-06 | 200 | 61 | 5 | dec9ce1bc2571197003596f32e5f742ede72aa79 | |
| ToppCell | Parenchymal-10x5prime-Stromal-Peri/Epineurial_-NAF_endoneurial|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 8.02e-06 | 200 | 61 | 5 | 8a4c210a3130f7baedf15ecbc0f4903b97da0352 | |
| ToppCell | Parenchyma_COVID-19-Stromal-TX|Parenchyma_COVID-19 / Sample group, Lineage and Cell type | 8.02e-06 | 200 | 61 | 5 | 8472baa74c48b67c5f08223025885c833458290b | |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 8.02e-06 | 200 | 61 | 5 | fb53be20392a8309a7393774c774a1b1aec6e676 | |
| ToppCell | Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 8.02e-06 | 200 | 61 | 5 | 58b38f9a484ee94191091a0659ed62ebed2d4a14 | |
| ToppCell | Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-1-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 8.02e-06 | 200 | 61 | 5 | dd4228cbed8a4395166a6332e08d44d88bebe3b9 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-high_Fibroblast-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 5.34e-05 | 150 | 61 | 4 | 1270f33f9d7e46e55adf1a96e8beee858b95589d | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen-high_Fibroblast|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 5.34e-05 | 150 | 61 | 4 | 156118ce1d69522624196410cba18b8354cd0bb4 | |
| ToppCell | Adult-Epithelial-basal_cell-D122|Adult / Lineage, Cell type, age group and donor | 5.92e-05 | 154 | 61 | 4 | 38d346402417960044ae999e61f0092b46f2b591 | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_airway-Ciliated_cells|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.07e-05 | 155 | 61 | 4 | 5f1e2195a6b831e1b636f5cc3a282ca423721822 | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_airway-Ciliated_cells-Ciliated|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 6.07e-05 | 155 | 61 | 4 | 0944429459f642a1bcc56edc1ec28aaecde3e2dc | |
| ToppCell | 3'-Distal_airway-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.3.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.70e-05 | 159 | 61 | 4 | 5543f5aec6352a7c5923e55daf3ed40ff5cc0f0c | |
| ToppCell | 3'-Distal_airway-Epithelial-Airway_epithelium-respiratory_basal_cell-Suprabasal-Suprabasal_L.0.0.2.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.70e-05 | 159 | 61 | 4 | 1baf0eaf9684668146a63192e77eec6c3c7a37f8 | |
| ToppCell | E16.5-samps-Mesenchymal-Matrix_fibroblast-_fetal-Mature_Fibroblast_1|E16.5-samps / Age Group, Lineage, Cell class and subclass | 7.38e-05 | 163 | 61 | 4 | f1ec2625b52664308968b01d8e0275e1e0751480 | |
| ToppCell | LPS-IL1RA+antiTNF-Epithelial_airway|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 7.55e-05 | 164 | 61 | 4 | e4d4c59aebe5cacd4ecdb907facd044dc82a831d | |
| ToppCell | Children_(3_yrs)-Mesenchymal-airway_smooth_muscle_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 7.55e-05 | 164 | 61 | 4 | e3983f655cdba308fb192182829f17bef99ce0ba | |
| ToppCell | Children_(3_yrs)-Endothelial-endothelial_cell_of_vein-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 8.10e-05 | 167 | 61 | 4 | d7fe24cdc4b55a9555ce9e20699f5036b88148e9 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-kidney_interstitial_fibroblast_5|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 8.29e-05 | 168 | 61 | 4 | d19a115365c5415e51c039718d7669de788fcf33 | |
| ToppCell | droplet-Lung-3m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l49|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 8.29e-05 | 168 | 61 | 4 | d2b91f2adc95dcfa623f8d7ca2df1c6f884da988 | |
| Disease | L lactate dehydrogenase measurement | 1.91e-05 | 26 | 59 | 3 | EFO_0004808 | |
| Disease | MHC class I polypeptide-related sequence B measurement | 2.97e-05 | 30 | 59 | 3 | EFO_0008234 | |
| Disease | PAX-interacting protein 1 measurement | 1.09e-04 | 8 | 59 | 2 | EFO_0801868 | |
| Disease | gdnf family receptor alpha-1 measurement | 1.09e-04 | 8 | 59 | 2 | EFO_0020400 | |
| Disease | lung adenocarcinoma (is_implicated_in) | 1.31e-04 | 49 | 59 | 3 | DOID:3910 (is_implicated_in) | |
| Disease | zinc fingers and homeoboxes protein 3 measurement | 1.40e-04 | 9 | 59 | 2 | EFO_0803299 | |
| Disease | Adult Hepatocellular Carcinoma | 1.40e-04 | 9 | 59 | 2 | C0279607 | |
| Disease | HLA class II histocompatibility antigen, DQ alpha 2 chain measurement | 1.40e-04 | 9 | 59 | 2 | EFO_0801686 | |
| Disease | cervical carcinoma, Cervical Intraepithelial Neoplasia Grade 2/3 | 1.75e-04 | 10 | 59 | 2 | EFO_0001061, EFO_1000166 | |
| Disease | ovarian cancer (is_marker_for) | 3.47e-04 | 68 | 59 | 3 | DOID:2394 (is_marker_for) | |
| Disease | natural cytotoxicity triggering receptor 3 measurement | 3.52e-04 | 14 | 59 | 2 | EFO_0008243 | |
| Disease | complement factor H measurement, protein binding measurement | 3.52e-04 | 14 | 59 | 2 | EFO_0008097, EFO_0010742 | |
| Disease | C-C motif chemokine 19 measurement | 3.52e-04 | 14 | 59 | 2 | EFO_0008047 | |
| Disease | mucocutaneous lymph node syndrome | 4.81e-04 | 76 | 59 | 3 | EFO_0004246 | |
| Disease | Graves disease, thyrotoxic periodic paralysis | 5.24e-04 | 17 | 59 | 2 | EFO_0004237, MONDO_0019201 | |
| Disease | Autoimmune Hepatitis | 8.05e-04 | 21 | 59 | 2 | EFO_0005676 | |
| Disease | hair morphology | 1.54e-03 | 29 | 59 | 2 | EFO_0005038 | |
| Disease | Thrombocytopenia | 1.54e-03 | 29 | 59 | 2 | C0040034 | |
| Disease | Epileptic encephalopathy | 1.65e-03 | 30 | 59 | 2 | C0543888 | |
| Disease | Schizophrenia | 1.85e-03 | 883 | 59 | 7 | C0036341 | |
| Disease | Autistic Disorder | 1.86e-03 | 261 | 59 | 4 | C0004352 | |
| Disease | rheumatic heart disease | 1.99e-03 | 33 | 59 | 2 | EFO_1001161 | |
| Disease | chronic hepatitis C virus infection | 1.99e-03 | 33 | 59 | 2 | EFO_0004220 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| TDHTTETAQGHYMVV | 846 | Q6UXC1 | |
| SDGAYIHRMQQEAQH | 121 | Q6PK04 | |
| SSDHGELAMEHRQFY | 311 | Q6UWY0 | |
| RHAQDTAEGDDVTYM | 121 | Q9P2B4 | |
| RNNAYGDHVNDSDTM | 316 | Q5JRM2 | |
| EENYHTPEFSQSHMS | 3081 | Q6V0I7 | |
| LNHYGMTHVASVSDV | 1206 | Q13085 | |
| SEDVYRSHVAGQMLH | 296 | P43155 | |
| QTEGQERTPTHYHML | 306 | P46597 | |
| EISHGVVAHMSDSYQ | 936 | P08603 | |
| MATGETNSVYHDDDN | 826 | Q9UKL3 | |
| YHLSQHGVFSEADMR | 281 | P25098 | |
| YSESHRVHRMQDFDG | 216 | Q96I51 | |
| EEQRFTCYMEHSGNH | 276 | Q29983 | |
| SHDAESFQMHITQEG | 476 | Q12913 | |
| ENEDMHGSGVTFHTY | 191 | P16389 | |
| QYIHDGSSTREDSME | 1671 | Q86XX4 | |
| QTQHPHYSREELNSM | 211 | Q9NYK6 | |
| NMEANSHYGHNDDVR | 656 | P16284 | |
| MEDTGHYSINDENRV | 81 | Q5TAQ9 | |
| EEQRFTCYMEHSGNH | 276 | Q29980 | |
| HSEDMNATRSEEQFH | 146 | Q9C0H6 | |
| YQASQHDMCRFHSED | 51 | O15379 | |
| NHMHLRTGLSTEYEE | 91 | Q96JM4 | |
| TYIHHASGTSMDQDR | 251 | P0DN82 | |
| HSTDRVSMHQDNHGY | 1276 | Q8WX93 | |
| INAHHAYESQISSMA | 936 | Q66GS9 | |
| SQEHSQEPERQYMHI | 956 | Q08462 | |
| GVVQYSHSQMQEHVS | 661 | P12109 | |
| EQLSSQHHYDYGMRA | 1591 | Q8TD57 | |
| QDIRHMHFDGTDYGT | 491 | P01133 | |
| QEYVASAMHGDSHDR | 91 | Q5T3F8 | |
| YTASNPEDEMQHVQH | 396 | Q56NI9 | |
| EAMCHYEDIRSHGNT | 591 | Q9NTJ4 | |
| QDGIEQHMDFDSRYT | 211 | Q8IWT3 | |
| DDMSVYAVGSHSHVS | 316 | Q5VU92 | |
| SHSRQYVSGLHMNRE | 396 | P35367 | |
| FGYRSVQGDHEMIHS | 111 | Q9UNU6 | |
| TEMDEHNRPIHTYQV | 61 | Q9UF33 | |
| VTHHDYRMELAQAGT | 381 | Q99932 | |
| NMEDLREQTHTRHYE | 281 | Q9NVA2 | |
| SVAEMSAYHHGEQAL | 771 | Q02880 | |
| YDQVLHEDETTNRMH | 231 | P09471 | |
| NSHMGQEIDSHDYVF | 376 | Q9NSC7 | |
| EQHMEYHSFSEQSFH | 81 | Q96JW4 | |
| TGVSQDHMRAHYQTG | 186 | P78383 | |
| YQMSIHLREDSSQTH | 496 | Q13733 | |
| GTMVEDHRSNSYQDS | 26 | Q6V9R5 | |
| DSVGQLHIMDYNETH | 1146 | Q92574 | |
| TVEELYSHMDSHQQP | 321 | Q96K83 | |
| THHLVTMQSGRQSYE | 441 | Q86VK4 | |
| NMEDLREQTHTRHYE | 306 | Q9P0V9 | |
| TVHMNETGHYQDDNR | 231 | Q9NRE2 | |
| VHMNETGHYRDDNHE | 231 | Q63HK5 | |
| NDSREHMIPEHQYQT | 781 | Q5HYM0 | |
| VREDSSGMHHENQTY | 881 | Q07157 | |
| DIQHRVHMEENSYNS | 431 | Q9UJU3 | |
| DEFRYQHEQMNATHT | 941 | Q15643 | |
| QSDHRSRHEVSHYSM | 1616 | Q70CQ2 | |
| LTVHMNETGHYRDDN | 261 | Q6ZSZ6 | |
| ENSVDTHGYREMVDS | 331 | Q5H9K5 | |
| DSNNFDGSHVYMHSD | 386 | Q9ULJ8 |